Welcome to LookChem.com Sign In|Join Free

CAS

  • or
N4-Acetylcytosine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

14631-20-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 14631-20-0 Structure
  • Basic information

    1. Product Name: N4-Acetylcytosine
    2. Synonyms: n-(1,2-dihydro-2-oxo-4-pyrimidinyl)-acetamid;N-ACETYLCYTOSINE;N4-ACETYLCYTOSINE;LABOTEST-BB LT00012625;4-Acetylamino-2-hydroxypyrimidine;N-Acetocytosine;N(4)-Acetylcytosine,98%;N-Actyl cytosine
    3. CAS NO:14631-20-0
    4. Molecular Formula: C6H7N3O2
    5. Molecular Weight: 153.14
    6. EINECS: 1806241-263-5
    7. Product Categories: Heterocyclic Compounds;Biochemistry;Nucleobases and their analogs;Nucleosides, Nucleotides & Related Reagents;Building Blocks;Heterocyclic Building Blocks;Pyrimidines
    8. Mol File: 14631-20-0.mol
  • Chemical Properties

    1. Melting Point: >300 °C(lit.)
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.41 g/cm3
    6. Refractive Index: 1.625
    7. Storage Temp.: Sealed in dry,Room Temperature
    8. Solubility: DMSO (Sparingly), Methanol (Very Slightly)
    9. PKA: 7.60±0.10(Predicted)
    10. BRN: 138451
    11. CAS DataBase Reference: N4-Acetylcytosine(CAS DataBase Reference)
    12. NIST Chemistry Reference: N4-Acetylcytosine(14631-20-0)
    13. EPA Substance Registry System: N4-Acetylcytosine(14631-20-0)
  • Safety Data

    1. Hazard Codes: Xi
    2. Statements: 36/37/38
    3. Safety Statements: 22-24/25-37/39-26-37
    4. WGK Germany: 3
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 14631-20-0(Hazardous Substances Data)

14631-20-0 Usage

Chemical Properties

Crstalline powder

Uses

N4-Acetylcytosine may be used in the preparation of cytidine. It may be used in the preparation of 1-(4-azido-4-deoxy-β-D-glucopyranosyl)cytosine.

General Description

Four stable conformers of N4-acetylcytosine, and the one of the stable form containing an intramoleuclar six-membered ring have been reported by theoretical calculations.The infrared and FT-Raman spectra of N4-acetylcytosine in the solid phase has been reported.

Purification Methods

If TLC or paper chromatography shows that it contains unacetylated cytosine, then reflux it in Ac2O for 4hours, cool at 3-4o for a few days, collect the crystals, wash them with cold H2O, then EtOH and dry at 100o. It is insoluble in EtOH and dissolves in H2O with difficulty, but crystallises in prisms from hot H2O. It is hydrolysed by 80% aqueous AcOH at 100o/1hour. [UV: Brown et al. J Chem Soc 2384 1956, Codington et al. J Am Chem Soc 80 5164 1958.] It forms an Hg salt [Fox et al. J Am Chem Soc 79 5060 1957]. [Beilstein 25 III/IV 3657.]

Check Digit Verification of cas no

The CAS Registry Mumber 14631-20-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,6,3 and 1 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 14631-20:
(7*1)+(6*4)+(5*6)+(4*3)+(3*1)+(2*2)+(1*0)=80
80 % 10 = 0
So 14631-20-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H7N3O2/c1-4(10)8-5-2-3-7-6(11)9-5/h2-3H,1H3,(H2,7,8,9,10,11)

14631-20-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (A2089)  N4-Acetylcytosine  >98.0%(T)

  • 14631-20-0

  • 5g

  • 305.00CNY

  • Detail
  • TCI America

  • (A2089)  N4-Acetylcytosine  >98.0%(T)

  • 14631-20-0

  • 25g

  • 990.00CNY

  • Detail
  • Alfa Aesar

  • (B20851)  N(4)-Acetylcytosine, 98%   

  • 14631-20-0

  • 5g

  • 284.0CNY

  • Detail
  • Alfa Aesar

  • (B20851)  N(4)-Acetylcytosine, 98%   

  • 14631-20-0

  • 25g

  • 1117.0CNY

  • Detail
  • Alfa Aesar

  • (B20851)  N(4)-Acetylcytosine, 98%   

  • 14631-20-0

  • 100g

  • 3493.0CNY

  • Detail
  • Aldrich

  • (377910)  N4-Acetylcytosine  99%

  • 14631-20-0

  • 377910-25G

  • 1,153.62CNY

  • Detail

14631-20-0Synthetic route

Cytosine
71-30-7

Cytosine

acetic anhydride
108-24-7

acetic anhydride

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

Conditions
ConditionsYield
With phosphoric acid at 100℃; for 8h;98%
With pyridine for 2.5h; Heating;97.2%
With pyridine at 20℃; for 24h;85%
4-Amino-1-(2,5-anhydro-β-D-arabinofuranosyl)pyrimidin-2(1H)-one
32830-01-6

4-Amino-1-(2,5-anhydro-β-D-arabinofuranosyl)pyrimidin-2(1H)-one

A

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

B

4-Acetamido-1-(2,3-di-O-acetyl-5-bromo-5-deoxy-β-D-arabinofuranosyl)pyrimidin-2(1H)-one
84856-79-1

4-Acetamido-1-(2,3-di-O-acetyl-5-bromo-5-deoxy-β-D-arabinofuranosyl)pyrimidin-2(1H)-one

C

4-Amino-1-(5-bromo-5-deoxy-β-D-arabinofuranosyl)pyrimidin-2(1H)-one
58538-06-0

4-Amino-1-(5-bromo-5-deoxy-β-D-arabinofuranosyl)pyrimidin-2(1H)-one

Conditions
ConditionsYield
With hydrogen bromide In N,N-dimethyl-formamide at 120℃; for 0.416667h;A 20%
B 3%
C 45%
N-acetylcytidine
3768-18-1

N-acetylcytidine

A

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

B

N4,O5'-diacetyl-2',3'-dideoxycytidine
120885-66-7

N4,O5'-diacetyl-2',3'-dideoxycytidine

C

N4-acetyl-5'-O-(acetoxyisobutyryl)-2',3'-dideoxycytidine
126430-20-4

N4-acetyl-5'-O-(acetoxyisobutyryl)-2',3'-dideoxycytidine

Conditions
ConditionsYield
Yield given. Multistep reaction. Yields of byproduct given;
N4-acetyl-O5'-trityl-2'deoxy-cytidine
40094-20-0

N4-acetyl-O5'-trityl-2'deoxy-cytidine

A

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

B

4,5-dihydro-5-trityloxymethylfuran-4-one
65475-52-7

4,5-dihydro-5-trityloxymethylfuran-4-one

Conditions
ConditionsYield
With pyridine; chromium(VI) oxide; acetic anhydride In dichloromethane Ambient temperature; 45 - 60 min;
4-acetylamino-1H-<2-14C>pyrimidin-2-one

4-acetylamino-1H-<2-14C>pyrimidin-2-one

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

Cytosine
71-30-7

Cytosine

acetyl chloride
75-36-5

acetyl chloride

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

Conditions
ConditionsYield
With pyridine; dmap In dichloromethane at 20℃; Inert atmosphere;
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

Me3SiX

Me3SiX

N4-acetyl-O-trimethylsilylcytosine
54230-57-8

N4-acetyl-O-trimethylsilylcytosine

Conditions
ConditionsYield
100%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

N-(1,2,2,2-tetrachloroethyl)benzamide
6798-35-2

N-(1,2,2,2-tetrachloroethyl)benzamide

N-[1-(4-Acetylamino-2-oxo-2H-pyrimidin-1-yl)-2,2,2-trichloro-ethyl]-benzamide
136506-88-2

N-[1-(4-Acetylamino-2-oxo-2H-pyrimidin-1-yl)-2,2,2-trichloro-ethyl]-benzamide

Conditions
ConditionsYield
With sodium hydroxide In water; acetone at 0℃; for 0.5h;99%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-D-erythro-pentofuranose
293751-03-8

1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-D-erythro-pentofuranose

(2R,3R,4S)-2-(4-acetamido-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5,5-bis(((methylsulfonyl)oxy)methyl)tetrahydrofuran-3-yl acetate
293751-17-4

(2R,3R,4S)-2-(4-acetamido-2-oxopyrimidin-1(2H)-yl)-4-(benzyloxy)-5,5-bis(((methylsulfonyl)oxy)methyl)tetrahydrofuran-3-yl acetate

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine; 1,2-di-O-acetyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-3-O-benzyl-D-erythro-pentofuranose With N,O-bis-(trimethylsilyl)-acetamide In acetonitrile for 1h; Reflux;
Stage #2: With trimethylsilyl trifluoromethanesulfonate In acetonitrile for 5.5h; Reflux; Inert atmosphere;
96%
Stage #1: 4-N-Acetylcytosine; 1,2-di-O-acetyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-3-O-benzyl-D-erythro-pentofuranose With N,O-bis-(trimethylsilyl)-acetamide In acetonitrile for 1h; Heating;
Stage #2: With trimethylsilyl trifluoromethanesulfonate In acetonitrile for 3h; Heating; Further stages.;
82%
With N,O-bis-(trimethylsilyl)-acetamide; trimethylsilyl trifluoromethanesulfonate In acetonitrile82%
Stage #1: 4-N-Acetylcytosine; 1,2-di-O-acetyl-5-O-methanesulfonyl-4-C-methanesulfonyloxymethyl-3-O-benzyl-D-erythro-pentofuranose With N,O-bis-(trimethylsilyl)-acetamide In acetonitrile at 40℃; for 0.333333h;
Stage #2: With trimethylsilyl trifluoromethanesulfonate In acetonitrile at 20℃; for 2.5h; Heating / reflux;
60%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5R)-5-(methylcarbonyloxy)-1,3-oxathiolane-2-carboxylate
147027-09-6

(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5R)-5-(methylcarbonyloxy)-1,3-oxathiolane-2-carboxylate

(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5S)-5-[4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl]-1,3-oxathiolane-2-carboxylate
147126-78-1

(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5S)-5-[4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl]-1,3-oxathiolane-2-carboxylate

Conditions
ConditionsYield
Stage #1: (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5R)-5-(methylcarbonyloxy)-1,3-oxathiolane-2-carboxylate With triethylsilane; iodine In dichloromethane at 0℃; for 1h; Inert atmosphere;
Stage #2: 4-N-Acetylcytosine With N,O-bis-(trimethylsilyl)-acetamide In dichloromethane at 0 - 20℃; for 1h; Reagent/catalyst; Inert atmosphere; stereoselective reaction;
95%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-bromo-6-hexanol
4286-55-9

1-bromo-6-hexanol

1-(6-hydroxy-hexyl)-N4-acetyl-cytosine

1-(6-hydroxy-hexyl)-N4-acetyl-cytosine

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide for 18h; Ambient temperature;91%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

5-((tert-butyl(diphenyl)silyl)oxy)-5,7-dimethoxy-2,3,5,7-tetrahydro[1,4]dithiino[2,3-c]furan

5-((tert-butyl(diphenyl)silyl)oxy)-5,7-dimethoxy-2,3,5,7-tetrahydro[1,4]dithiino[2,3-c]furan

N1-(1-(7-((tert-butyl(diphenyl)silyl)oxy)methyl)-7-methoxy-2,3,5,7-tetrahydro[1,4]dithiino[2,3-c]furan-5-yl-2-oxo-1,2-dihydro-4-pyrimidinyl)acetamide

N1-(1-(7-((tert-butyl(diphenyl)silyl)oxy)methyl)-7-methoxy-2,3,5,7-tetrahydro[1,4]dithiino[2,3-c]furan-5-yl-2-oxo-1,2-dihydro-4-pyrimidinyl)acetamide

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine; 5-((tert-butyl(diphenyl)silyl)oxy)-5,7-dimethoxy-2,3,5,7-tetrahydro[1,4]dithiino[2,3-c]furan With N,O-bis-(trimethylsilyl)-acetamide In acetonitrile at 50℃; for 0.5h; Vorbrueggen Nucleoside Synthesis; Inert atmosphere;
Stage #2: With trimethylsilyl trifluoromethanesulfonate In acetonitrile at 20℃; for 0.166667h; Inert atmosphere;
91%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

5-O-benzoyl-3-deoxy-1,2-di-O-acetyl-α,β-D-erythro-pentofuranose
4613-71-2

5-O-benzoyl-3-deoxy-1,2-di-O-acetyl-α,β-D-erythro-pentofuranose

3'-deoxycytidine
7057-33-2

3'-deoxycytidine

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine; 5-O-benzoyl-3-deoxy-1,2-di-O-acetyl-α,β-D-erythro-pentofuranose With benzenesulfonamide In acetonitrile for 1h; Heating;
Stage #2: With trimethylsilyl trifluoromethanesulfonate at 20℃; for 5h;
Stage #3: With ammonium hydroxide In tetrahydrofuran; methanol at 50℃; for 6h; Further stages.;
90%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

5-iodopent-1-yne
2468-55-5

5-iodopent-1-yne

1-(1-Pentynyl)-N4-acetylcytosine

1-(1-Pentynyl)-N4-acetylcytosine

Conditions
ConditionsYield
With potassium carbonate; dimethyl sulfoxide In tetrahydrofuran at 20℃; for 22h; Alkylation;88%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

2-deoxy-2,2-difluoro-3-benzoyl-5-(2-naphthoyl)-1-methanesulfonyloxy-D-ribofuranose

2-deoxy-2,2-difluoro-3-benzoyl-5-(2-naphthoyl)-1-methanesulfonyloxy-D-ribofuranose

1-2'-deoxy-2',2'-difluoro-3-benzoyl-5-(2-naphthoyl)-D-ribofuranosyl-4-(1-acetyl)aminopyrimidin-2-one

1-2'-deoxy-2',2'-difluoro-3-benzoyl-5-(2-naphthoyl)-D-ribofuranosyl-4-(1-acetyl)aminopyrimidin-2-one

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With chloro-trimethyl-silane; 1,1,1,3,3,3-hexamethyl-disilazane In toluene for 3h; Heating / reflux;
Stage #2: 2-deoxy-2,2-difluoro-3-benzoyl-5-(2-naphthoyl)-1-methanesulfonyloxy-D-ribofuranose With trimethylsilyl trifluoromethanesulfonate In toluene for 15h; Heating / reflux;
88%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

acetic anhydride
108-24-7

acetic anhydride

N-acetyl-5-acetylcytosine

N-acetyl-5-acetylcytosine

Conditions
ConditionsYield
With boron trifluoride diethyl etherate In chloroform at 100℃;88%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-iodo-2,2,3,3,4,4,5,5,5-nonafluorobutane
423-39-2

1-iodo-2,2,3,3,4,4,5,5,5-nonafluorobutane

N-(2-oxo-5-(perfluorobutyl)-1,2-dihydropyrimidin-4-yl)acetamide

N-(2-oxo-5-(perfluorobutyl)-1,2-dihydropyrimidin-4-yl)acetamide

Conditions
ConditionsYield
With caesium carbonate In dimethyl sulfoxide at 20℃; for 24h; Schlenk technique; Inert atmosphere; Irradiation;87%
Conditions
ConditionsYield
With benzenesulfonamide; trimethylsilyl trifluoromethanesulfonate In acetonitrile at 65℃;86%
Substitution;86%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

allyl bromide
106-95-6

allyl bromide

N4-acetyl-N1-allylcytosine

N4-acetyl-N1-allylcytosine

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 24h;86%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1,4-anhydro-2-deoxy-3,5-di-O-(di-tert-butylsilylene)-1-C-(triethylsilyloxy-methyl)-D-erythro-pent-1-enitol
1235869-94-9

1,4-anhydro-2-deoxy-3,5-di-O-(di-tert-butylsilylene)-1-C-(triethylsilyloxy-methyl)-D-erythro-pent-1-enitol

N4-acetyl-1-[3,5-O-(di-tert-butylsilylene)-2-deoxy-2-iodo-1-C-(triethyl-silyloxymethyl)-β-D-ribofuranosyl]cytosine
1235870-16-2

N4-acetyl-1-[3,5-O-(di-tert-butylsilylene)-2-deoxy-2-iodo-1-C-(triethyl-silyloxymethyl)-β-D-ribofuranosyl]cytosine

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With N,O-bis-(trimethylsilyl)-acetamide In acetonitrile
Stage #2: 1,4-anhydro-2-deoxy-3,5-di-O-(di-tert-butylsilylene)-1-C-(triethylsilyloxy-methyl)-D-erythro-pent-1-enitol With N-iodo-succinimide In dichloromethane; acetonitrile at 0℃; for 12h; Inert atmosphere; stereoselective reaction;
84%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

ethyl acrylate
140-88-5

ethyl acrylate

ethyl 3-(4-acetamido-2-oxopyrimidin-1(2H)-yl)propanoate
38718-22-8

ethyl 3-(4-acetamido-2-oxopyrimidin-1(2H)-yl)propanoate

Conditions
ConditionsYield
With tetrabutylammomium bromide; zinc(II) oxide at 100℃; for 0.416667h; Michael addition; microwave irradiation;83%
With tetrabutylammomium bromide at 100℃; for 0.416667h; Microwave irradiation; Neat (no solvent);81%
With Bacillus subtilis alkaline protease EC 3.4.21.14 In dimethyl sulfoxide at 50℃; for 24h; Michael addition;28.7%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

acrylonitrile
107-13-1

acrylonitrile

C9H10N4O2

C9H10N4O2

Conditions
ConditionsYield
With triethylamine In water at 100℃; for 0.0833333h; Michael addition; microwave irradiation;83%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

(E)-4-bromo-2-benzoyloxymethyl-1-fluorobut-1-ene
167629-23-4

(E)-4-bromo-2-benzoyloxymethyl-1-fluorobut-1-ene

(E)-4-(4-acetylaminopyrimidinone-1-yl)-2-benzoyloxymethyl-1-fluorobut-1-ene
208719-58-8

(E)-4-(4-acetylaminopyrimidinone-1-yl)-2-benzoyloxymethyl-1-fluorobut-1-ene

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 80℃; for 18h;81%
3-[(tert-butyldiphenylsilyloxy)methyl]-2-methylisoxazolidin-5-yl acetate

3-[(tert-butyldiphenylsilyloxy)methyl]-2-methylisoxazolidin-5-yl acetate

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-[(1'SR,4'RS)-(4'-((tert-butyldiphenylsilyloxy)methyl)-3'-methyl)-2'-oxa-3'-azacyclopent-1'-yl]-4-(acetylamino)-2-oxo-1,2-dihydropyrimidine

1-[(1'SR,4'RS)-(4'-((tert-butyldiphenylsilyloxy)methyl)-3'-methyl)-2'-oxa-3'-azacyclopent-1'-yl]-4-(acetylamino)-2-oxo-1,2-dihydropyrimidine

1-[(1'RS,4'RS)-(4'-((tert-butyldiphenylsilyloxy)methyl)-3'-methyl)-2'-oxa-3'-azacyclopent-1'-yl]-4-(acetylamino)-2-oxo-1,2-dihydropyrimidine

1-[(1'RS,4'RS)-(4'-((tert-butyldiphenylsilyloxy)methyl)-3'-methyl)-2'-oxa-3'-azacyclopent-1'-yl]-4-(acetylamino)-2-oxo-1,2-dihydropyrimidine

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With bis-(trimethylsilyl)acetamide In acetonitrile at 20℃; for 0.5h;
Stage #2: 3-[(tert-butyldiphenylsilyloxy)methyl]-2-methylisoxazolidin-5-yl acetate; trimethylsilyl trifluoromethanesulfonate In acetonitrile at 20℃; for 24h; Further stages.;
A 80%
B 10%
piperidine
110-89-4

piperidine

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

N-(2-(piperidin-1-yl)pyrimidin-4-yl)acetamide

N-(2-(piperidin-1-yl)pyrimidin-4-yl)acetamide

Conditions
ConditionsYield
With copper acetylacetonate; di-tert-butyl peroxide; N,N-dimethyl-formamide at 100℃; for 10h; Green chemistry;79%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

C7H10O3S2
1257249-09-4

C7H10O3S2

{5-(4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl)-5,6-dihydro-1,4-dithiin-2-yl}methyl acetate
1257249-10-7

{5-(4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl)-5,6-dihydro-1,4-dithiin-2-yl}methyl acetate

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With trimethylsilyl trifluoromethanesulfonate; triethylamine In dichloromethane at 0 - 20℃; Pummerer type glycosidation; Inert atmosphere;
Stage #2: C7H10O3S2 In dichloromethane at 0 - 20℃; Pummerer type glycosidation; Inert atmosphere;
78%
2,3,4,6-tetra-O-benzoylglucosyl bromide
14218-11-2

2,3,4,6-tetra-O-benzoylglucosyl bromide

4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

β-N-acetylcytosyl-2',3',4',6'-tetrabenzoylglucose

β-N-acetylcytosyl-2',3',4',6'-tetrabenzoylglucose

Conditions
ConditionsYield
With mercury(II) cyanide In nitromethane for 4.5h; Heating;77%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

7-((5-(chloromethyl)-1,3,4-oxadiazol-2-yl)methyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione

7-((5-(chloromethyl)-1,3,4-oxadiazol-2-yl)methyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione

N-(1-((5-((1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)methyl)-1,3,4-oxadiazol-2-yl)methyl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide

N-(1-((5-((1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)methyl)-1,3,4-oxadiazol-2-yl)methyl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 60℃; for 2h;76%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1,4-anhydro-2-O-(2,4-dimethoxybenzoyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-4-sulfinyl-D-ribitol
869347-03-5

1,4-anhydro-2-O-(2,4-dimethoxybenzoyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-4-sulfinyl-D-ribitol

N4-acetyl-1-[2-O-(2,4-dimethoxybenzoyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-4-thio-β-D-ribofuranosyl]cytosine
291758-17-3

N4-acetyl-1-[2-O-(2,4-dimethoxybenzoyl)-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-4-thio-β-D-ribofuranosyl]cytosine

Conditions
ConditionsYield
With trimethylsilyl trifluoromethanesulfonate In dichloromethane; toluene at 20℃; for 0.0833333h; Pummerer reaction;75%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-bromo-hexane
111-25-1

1-bromo-hexane

N-(1-hexyl-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide
895163-82-3

N-(1-hexyl-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 80℃; for 16h;75%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

chloroacetic acid ethyl ester
105-39-5

chloroacetic acid ethyl ester

N4-acetyl-1-(ethoxycarbonylmethyl)cytosine
870122-95-5

N4-acetyl-1-(ethoxycarbonylmethyl)cytosine

Conditions
ConditionsYield
With potassium carbonate In acetone for 5h; Heating;75%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

C7H10O3S2
1257249-11-8

C7H10O3S2

{6-(4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl)-5,6-dihydro-1,4-dithiin-2-yl}methyl acetate
1257249-12-9

{6-(4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl)-5,6-dihydro-1,4-dithiin-2-yl}methyl acetate

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With trimethylsilyl trifluoromethanesulfonate; triethylamine In dichloromethane at 0 - 20℃; Inert atmosphere;
Stage #2: C7H10O3S2 In dichloromethane at 0 - 20℃; Inert atmosphere;
75%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1,2,3,5-tetra-O-benzoyl-2-C-trimethylsilylethynyl-β-D-ribofuranose
188413-93-6

1,2,3,5-tetra-O-benzoyl-2-C-trimethylsilylethynyl-β-D-ribofuranose

N4-acetyl-2',3',5'-tri-O-benzoyl-2'-C-[(trimethylsilyl)ethynyl]cytidine
188413-87-8

N4-acetyl-2',3',5'-tri-O-benzoyl-2'-C-[(trimethylsilyl)ethynyl]cytidine

Conditions
ConditionsYield
With N,O-bis-(trimethylsilyl)-acetamide; tin(IV) chloride In acetonitrile for 3.5h; Heating;73%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-dodecylbromide
143-15-7

1-dodecylbromide

N-(1-dodecyl-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide
1258960-67-6

N-(1-dodecyl-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide

Conditions
ConditionsYield
Stage #1: 4-N-Acetylcytosine With potassium carbonate In N,N-dimethyl-formamide for 0.5h;
Stage #2: 1-dodecylbromide In N,N-dimethyl-formamide at 80℃; for 24h;
71%
4-N-Acetylcytosine
14631-20-0

4-N-Acetylcytosine

1-(t-butyl-dimethylsilyloxymethyl)-3(R,S)-hydroxybicyclo[2,1,1]hexane
305819-10-7

1-(t-butyl-dimethylsilyloxymethyl)-3(R,S)-hydroxybicyclo[2,1,1]hexane

N-{1-[4-(tert-butyl-dimethyl-silanyloxymethyl)-bicyclo[2.1.1]hex-2-yl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-acetamide
305819-13-0

N-{1-[4-(tert-butyl-dimethyl-silanyloxymethyl)-bicyclo[2.1.1]hex-2-yl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-acetamide

Conditions
ConditionsYield
With triphenylphosphine; diethylazodicarboxylate In tetrahydrofuran at 20℃; Condensation; Mitsunobu reaction;70%

14631-20-0Relevant articles and documents

Synthesis, physicochemical characteristics, and biocompatibility of self-assemble polymers bearing guanine, cytosine, uracil, and thymine moieties

Kim, Jin Chul,Kim, Mihee,Jung, Jungwoon,Lee, Jinseok,Ree, Brian J.,Kim, Heesoo,Kim, Ik Jung,Kim, Jung Ran,Ree, Moonhor

, p. 1151 - 1160 (2015)

We synthesized chemically well-defined brush (i.e., comb-like) polymers bearing guanine, cytosine, uracil, or thymine moieties at the bristle ends. The polymers were stable up to 220 °C and were readily solution-processable, yielding high-quality films. Interestingly, the brush polymers favorably self-assembled to form molecular multibilayer structures stabilized by hydrogen bonding interactions among the nucleobase moieties at the bristle ends, which provided nucleobase-rich surfaces. The multibilayer-structured polymer films showed high water affinity. They also displayed selective protein adsorption, suppressed bacterial adherence, facilitated cell adhesion, and exhibited good biocompatibility in mice. The brush polymer DNA-mimicking comb-like polymers are suitable as biomaterials and in protein separation applications.

Synthesis of N4-β-D-glycoside cytosines and sugar N 4-acetylcytosin-1-ylmethylhydrazones as antiviral agents

Ali, Omar M.,Amer, Hamada H.,Abdel-Rahman, Adel A.-H.

, p. 281 - 283 (2007)

Reaction of monosaccharide aldoses with cytosine (1) gave stereoselectively β-N-glycosides 2a-d, which were treated with acetic anhydride in pyridine to afford the corresponding acetylated derivatives 3a-d. N4- Acetylcytosine (4) was synthesised and treated with ethyl chloroacetatete give 1-(ethoxycarbonylmethy)-N4-acetylcytosine (5). Hydrolysis of the latter ester with hydrazine hydrate afforded the hydrazide derivative 6. Condensation of the hydrazide with monosaccharide aldoses gave the corresponding sugar hydrazones 7a-f. Acetylation of the hydrazones afforded the per-O-acetyl derivatives 8a-f. The prepared compounds were tested for antiviral activity against hepatitis B virus (HBV) which showed moderate activities.

Discovery of α-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels

Routaboul, Christel,Norez, Caroline,Melin, Patricia,Molina, Marie-Carmen,Boucherle, Benjamin,Bossard, Florian,Noel, Sabrina,Robert, Renaud,Gauthier, Chantal,Becq, Frederic,Decout, Jean-Luc

, p. 1023 - 1035 (2007)

The cystic fibrosis transmembrane conductance regulator (CFTR) represents the main Cl- channel in the apical membrane of epithelial cells for cAMP-dependent Cl- secretion. Here we report on the synthesis and screening of a small library of nontoxic α-aminoazaheterocycle- methylglyoxal adducts, inhibitors of wild-type (WT) CFTR and G551D-, G1349D-, and F508del-CFTR Cl- channels. In whole-cell patch-clamp experiments of Chinese hamster ovary (CHO) cells expressing WT-CFTR, we recorded rapid and reversible inhibition of forskolin-activated CFTR currents in the presence of the adducts 5a and 8a,b at 10 pM concentrations. Using iodide efflux experiments, we compared concentration-dependent inhibition of CFTR with glibenclamide (IC50 = 14.7 μM), 3-[(3-trifluoromethyl)phenyl]-5- [(4-carboxyphenyl-)methylene]-2-thioxo-4-thiazolidinone (CFTRinh-172) (IC50 = 1.2 μM), and α-aminoazaheterocycle-methylglyoxal adducts and identified compounds 5a (IC50 = 71 pM), 8a,b (IC 50 = 2.5 nM), and 7a,b (IC50 = 3.4 nM) as the most potent inhibitors of WT-CFTR channels. Similar ranges of inhibition were also found when these compounds were evaluated on CFTR channels with the cystic fibrosis mutations F508del (in temperature-corrected human airway epithelial F508del/F508del CF15 cells)-, G551D-, and G1349D-CFTR (expressed in CHO and COS-7 cells). No effect of compound 5a was detected on the volume-regulated or calcium-regulated iodide efflux. Picomolar inhibition of WT-CFTR with adduct 5a was also found using a 6-methoxy-N-(3-sulfopropyl)-quinolinium fluorescent probe applied to the human tracheobronchial epithelial cell line 16HBE14o-. Finally, we found comparable inhibition by 5a or by CFTRinh-172 of forskolin-dependent short-circuit currents in mouse colon. To the best of our knowledge, these new nontoxic α-aminoazaheterocycle-methylglyoxal adducts represent the most potent compounds reported to inhibit CFTR chloride channels. Copyright

N -Glycosylation with sulfoxide donors for the synthesis of peptidonucleosides

Beau, Jean-Marie,Beretta, Margaux,Dr?ge, Thomas,Es-Sayed, Mazen,Nicolas, Lionel,Norsikian, Stéphanie,Rouchaud, Emilie,Vors, Jean-Pierre

supporting information, p. 4285 - 4291 (2021/05/31)

The synthesis of glycopyranosyl nucleosides modified in the sugar moiety has been less frequently explored, notably because of the lack of a reliable method to glycosylate pyrimidine bases. Herein we report a solution in the context of the synthesis of peptidonucleosides. They were obtained after glycosylation of different pyrimidine nucleobases with glucopyranosyl donors carrying an azide group at the C4 position. A methodological study involving different anomeric leaving groups (acetate, phenylsulfoxide and ortho-hexynylbenzoate) showed that a sulfoxide donor in combination with trimethylsilyl triflate as the promoter led to the best yields.

Preparation method for synthesizing palbociclib intermediate and method for synthesizing palbociclib

-

Paragraph 0018, (2020/09/30)

The invention discloses a preparation method of a novel palbociclib intermediate. The method is characterized by comprising the following steps: taking cytosine as a raw material, through protection of the amino group of cytosine, using an acetylation agent to perform acylation to obtain a 5- acetylation product in the presence of a Lewis acid or other acidic reagents, performing de-protection toobtain 5-acetylcytosine, and performing bromo-cyclopentane substitution and methyl acetoacetate cyclization to obtain a key pyridopyrimidine intermediate, which can be used for preparing palbociclib.The method has the advantages of short reaction route, cheap and easily available cytosine serving as an initial raw material, mild reaction conditions, high total yield, suitability for industrial production, and the like.

Stereoselective N-glycosylation with N4-acyl cytosines and efficient synthesis of gemcitabine

Liu, Tongchao,Tang, Jiadeng,Liang, Jianpeng,Chen, Yabin,Wang, Xiaowen,Shen, Jingkang,Zhao, Dongmei,Xiong, Bing,Cen, Jun-Da,Chen, Yue-Lei

, p. 1203 - 1213 (2019/01/29)

Through systematical comparison of various N4-protected cytosine derivatives in the glycosylation step of gemcitabine synthesis, highly beta-stereoselective and high yielding TBAI catalyzed N-glycosylation was achieved with N4-Bz cytosine and anomeric mixture of 2,2‘-difluororibose mesylate donor. The subsequent global deprotection gave gemcitabine efficiently. Meanwhile, the anomeric chloride intermediate and fluoride-displaced side products of this N-glycosylation were identified, too. This new glycosylation method reveals the importance of N4-protection in the stereoselective preparation of pyrimidine nucleoside, also provides a potential alternative to current industrial process to gemcitabine.

Synthesis and in vitro activity of N-sulfonylamidine-derived Pyrimidine Analogues

Krstulovi?, Luka,Safti?, Dijana,Ismaili, Hamit,Baji?, Miroslav,Glava?-Obrovac, Ljubica,?ini?, Biserka

, p. 625 - 636 (2018/05/07)

Two novel series of N-sulfonylamidino pyrimidine derivatives were synthesized via Cu-catalyzed three-component reaction of propargylated nucleobases with different benzenesulfonyl azides and amines. In this way 4-acetamido, 4 -methyl and 4-carboxybenzenesulfonyl amidine products 15-26 in the uracil series and 4-acetamidobenzenesulfonyl amidine derivatives 27-29 in the cytosine series were prepared in 34-69 % yields. Attempts to prepare N-sulfonylamidino cytosine derivatives in reaction with 4-methylbenzenesulfonyl azide were unsuccessful. The cytosine derivatives 32 and 33 were prepared from the N-sulfonylamidino uracil derivatives via the C4 triazole intermediates. The prepared N-sulfonylamidino pyrimidine derivatives 1-28 were tested for the antiproliferative activity on a panel of seven tumor cell lines of different histological origin (HeLa, Caco-2, NCI-H358, Raji, HuT78, K562, Jurkat) and on normal MDCK I cells. Most of the synthesized compounds showed antiproliferative activity on the tested cell lines.

PROCESS FOR PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE

-

Page/Page column 8, (2011/11/30)

The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.

PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE

-

Page/Page column 18, (2010/08/08)

The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.

Method for the treatment or prevention of viral infection using nucleoside analogues

-

, (2008/06/13)

Compounds of formula I: wherein Y, X, R1 and Ra are defined herein are in methods for treating or preventing a viral infections selected from herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus infections.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14631-20-0